Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Institutional Investor Sentiment Trend

November 14, 2017 - By reb123z

 Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Institutional Investor Sentiment Trend

Sentiment for Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

Progenics Pharmaceuticals Inc (NASDAQ:PGNX) institutional sentiment decreased to 1.29 in 2017 Q2. Its down -0.76, from 2.05 in 2017Q1. The ratio dived, as 76 investment professionals started new or increased equity positions, while 59 sold and trimmed holdings in Progenics Pharmaceuticals Inc. The investment professionals in our partner’s database now hold: 61.90 million shares, down from 64.17 million shares in 2017Q1. Also, the number of investment professionals holding Progenics Pharmaceuticals Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 23 Reduced: 36 Increased: 54 New Position: 22.

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The company has market cap of $371.02 million. The Company’s pipeline includes therapeutic agents designed to target cancer ; prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It currently has negative earnings. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation.

About 873,125 shares traded. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since November 14, 2016 and is uptrending. It has outperformed by 31.71% the S&P500.

Analysts expect Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report $-0.21 EPS on March, 8.They anticipate $0.11 EPS change or 110.00 % from last quarter’s $-0.1 EPS. After having $-0.22 EPS previously, Progenics Pharmaceuticals, Inc.’s analysts see -4.55 % EPS growth.

Phocas Financial Corp. holds 1.03% of its portfolio in Progenics Pharmaceuticals, Inc. for 1.47 million shares. Broadfin Capital Llc owns 1.00 million shares or 0.83% of their US portfolio. Moreover, Ardsley Advisory Partners has 0.62% invested in the company for 510,000 shares. The California-based Rice Hall James & Associates Llc has invested 0.4% in the stock. Park West Asset Management Llc, a California-based fund reported 907,351 shares.#img1#

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ratings Coverage

Ratings analysis reveals 100% of Progenics Pharm’s analysts are positive. Out of 5 Wall Street analysts rating Progenics Pharm, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $9 while the high is $15. The stock’s average target of $13.75 is 159.43% above today’s ($5.3) share price. PGNX was included in 11 notes of analysts from August 6, 2015. The rating was maintained by Needham on Tuesday, June 20 with “Buy”. Cantor Fitzgerald maintained the shares of PGNX in report on Wednesday, August 9 with “Buy” rating. The rating was maintained by Needham on Friday, August 7 with “Buy”. Jefferies maintained the shares of PGNX in report on Tuesday, September 26 with “Buy” rating. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Thursday, August 6 by Brean Capital. The firm has “Buy” rating by Jefferies given on Thursday, June 8. The firm has “Buy” rating given on Friday, August 7 by Zacks. Jefferies upgraded the shares of PGNX in report on Friday, October 23 to “Buy” rating. The company was upgraded on Monday, February 6 by Needham. Aegis Capital initiated the shares of PGNX in report on Thursday, October 27 with “Buy” rating.

More notable recent Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) news were published by: Globenewswire.com which released: “Progenics Pharmaceuticals Sets Third Quarter 2017 Financial Results Call for …” on October 23, 2017, also Seekingalpha.com with their article: “Progenics Pharmaceuticals: Prospects Look Bright” published on November 03, 2017, Seekingalpha.com published: “Progenic’s Azedra SPA: 2 Dose Monte” on November 09, 2017. More interesting news about Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were released by: Seekingalpha.com and their article: “Your Daily Pharma Scoop: Progenics Looks Promising, Big Week For Dynavax …” published on November 06, 2017 as well as Globenewswire.com‘s news article titled: “Progenics Pharmaceuticals to Participate in November Investor Conferences” with publication date: October 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.